Fig. 2From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitisComparison of changes of each item between the 12-month period in Pre-MPZ and Post-MPZ. a Changes in BVAS, b increase in VDI, c reduction in peripheral eosinophil counts (/μL), and d accumulated concomitant CS dose (mg/year). BVAS, Birmingham vasculitis activity score; CS, corticosteroid; VDI, vasculitis damage index. P values were determined by Wilcoxon signed-rank test. *P < 0.05: Pre-MPZ vs. Post-MPZBack to article page